August 2012
-
According to Perrigo, the FDA has approved its NDA for Nasonex 24HR Allergy mometasone furoate nasal spray for the treatment of allergy symptoms, the first branded Rx-to-OTC switch for Perrigo, and the company expects to launch… Read more . . .
-
RDD 2022 (May 1-5 in Orlando, Florida) will be the first major OINDP meeting to take place primarily in person since the beginning of the COVID-19 pandemic. According to Richard Dalby of RDD Online, organizers… Read more . . .
-
TFF Pharmaceuticals said that the company has entered into an additional Cooperative Research and Development Agreement (CRADA) with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Geneva Foundation for formulation of an intranasal dry powder… Read more . . .
-
The FDA has approved a generic version of AstraZeneca’s Symbicort budesonide / formoterol fumarate MDI from Mylan (now Viatris), the agency announced. The FDA tentatively approved the Mylan ANDA in March 2021 just after a… Read more . . .
-
Declaring that it is “determined to grow its portfolio in the complex generics space,” Novartis generics division Sandoz announced its acquisition of device device developer Coalesce Product Development. Coalesce’s inhaler technology include MDI, breath-actuated MDI,… Read more . . .
-
Researchers from the University of Liverpool have partnered with nebulizer maker Aerogen on a project called “Treatment of Respiratory Infections with inhaled AntimicrobiaLs” (TRIAL), which will develop inhaled therapies for the treatment of bacterial and… Read more . . .
-
Inhaler monitoring company Adherium has announced the submission of a 510(k) for a new Hailie sensor designed specifically for use with Ellipta DPIs. In September 2021, the FDA cleared another version of the next generation… Read more . . .
-
According to Optinose, the Phase 3 ReOpen1 trial of Xhance intranasal fluticasone propionate (OPN-375) in patients with chronic sinusitus met both of its primary endpoints, demonstrating statistically significant reduction in symptoms and in sinus inflammation… Read more . . .
-
Tonix Pharmaceuticals has provided updates on two formulations of its intranasal potentiated oxytocin. The company acquired the license for one of the formulations, TNX-1900 for the treatment of migraine, from Trigemina in June 2020. According… Read more . . .
-
Device maker HCmed Innovations has partnered with Formosa Laboratories and Formosa Pharmaceuticals to offer contract development and manufacturing services for inhaled drugs, HCmed announced. Formosa Laboratories already offers CDMO services for pharmaceutical products; the new… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.